Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1019 - Clinical association of antibiotics in immune check point inhibitors for advanced cancer treatment

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Hyunho Kim

Citation

Annals of Oncology (2018) 29 (suppl_9): ix170-ix172. 10.1093/annonc/mdy433

Authors

H. Kim, I. Kim

Author affiliations

  • Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 06591 - Seoul/KR
More

Resources

Abstract 1019

Background

Intestinal microbiota are important to control the systemic immune system. Antibiotics alter gut microbiota diversity and composition. Recent studies reported that the dysbiosis can lead to resistance to immune checkpoint inhibitors (ICI).

Methods

We examined 199 patients. They had NSCLC, melanoma, gastric, esophageal, RCC, bladder, and other cancers. Those receiving antibiotics within 30 days of beginning ICI were compared with those who did not. ICI were nivolumab (67.8%), pembrolizumab, and atezolizumab. We assessed objective response, and median overall survival (mOS). Only 118 patients were evaluated for response.

Results

NSCLC was the most common with 58.7% (118 of 199). 57 of 199 (29%) received antibiotics within 30 days of beginning ICI. Antibiotics were commonly cephalosporins and most were used for more than 7 days. In response evaluation, antibiotic compared with no antibiotic was not associated progression (41% vs 50%, p = 0.66). In total patients, antibiotics showed shorter mOS (5vs14months, p = 0.002, HR 1.93 95% CI 1.2-3.0). In NSCLC, antibiotics had also shorter mOS (4vs17monts, p = 0.008, HR 2.1, 95%CI 1.2-3.7). Those receiving antibiotics 30 to 60 days before beginning ICI showed no difference in mOS (8vs17months, p = 0.224).

Conclusions

Antibiotics were associated with poor clinical outcomes from ICI in various cancer, especially NSCLC. Modulation of antibiotic-related changes of gut microbiota may be important to improve clinical outcomes in ICI for cancer treatment.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The Catholic University of Korea, Seoul St. Mary\'s Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.